Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

Monday, October 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines Ltd. will present data from its solid tumor portfolio at the ESMO Congress 2026 in Madrid. The presentations will focus on their accelerating pipeline of targeted therapies, including significant evidence for TEVIMBRA® (tislelizumab). This event highlights the company's commitment to advancing oncology treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • BeOne Medicines is showcasing a rapidly progressing solid tumor portfolio.
  • The company is presenting differentiated targeted therapies at ESMO 2026.
  • TEVIMBRA® (tislelizumab) has a broad body of evidence supporting its use.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
3.3%
average across 6 past catalysts
Lead asset
BGB-43395
Phase 3 · HR+/HER2- Breast Cancer

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-bre

Frequently Asked Questions

What will BeOne Medicines present at ESMO 2026?

BeOne Medicines will present data from its solid tumor portfolio at ESMO 2026.

When is the ESMO Congress 2026?

The ESMO Congress 2026 will take place from October 23-27 in Madrid.

What is TEVIMBRA®?

TEVIMBRA® (tislelizumab) is a targeted therapy with significant evidence supporting its use.

What is the focus of BeOne Medicines' presentations?

The presentations will highlight their accelerating pipeline of differentiated targeted therapies.

ShareAdd on Google
Tags: ONC BeOne Medicines solid tumors ESMO 2026 TEVIMBRA oncology
Last updated: Oct 19, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
BGB-43395Phase 3
HR+/HER2- Breast Cancer →

Catalyst track record

+45%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →